CASI Pharmaceuticals (CASI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CASI Stock Forecast

CASI Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 12.36% upside from CASI’s last price of $5.34) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CASI Price Target

The average price target for CASI Pharmaceuticals (CASI) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 12.36% upside from CASI's last price of $5.34.

CASI Analyst Ratings

Buy

According to 2 Wall Street analysts, CASI Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CASI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CASI Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 15, 2024	Sean Lee	H.C. Wainwright	$6.00	$3.26	83.82%	12.36%
Aug 15, 2022	-	H.C. Wainwright	$12.00	$4.02	198.51%	124.72%

Row per page

Go to

The latest CASI Pharmaceuticals stock forecast, released on May 15, 2024 by Sean Lee from H.C. Wainwright, set a price target of $6.00, which represents a 83.82% increase from the stock price at the time of the forecast ($3.26), and a 12.36% increase from CASI last price ($5.34).

CASI Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$5.34	$5.34	$5.34
Upside/Downside	-100.00%	-100.00%	12.36%

In the current month, the average price target of CASI Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CASI Pharmaceuticals's last price of $5.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 16, 2022	BTIG	Buy	Buy	Hold
Jun 03, 2022	BTIG	Buy	Buy	Hold

Row per page

Go to

CASI Pharmaceuticals's last stock rating was published by H.C. Wainwright on May 15, 2024. The company gave CASI a "Buy" rating, the same as its previous rate.

CASI Pharmaceuticals Financial Forecast

CASI Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Mar 19	Jun 15	Mar 05	Mar 04
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$15.26M	$10.21M	$8.57M	$9.06M	$9.16M	$8.11M	$7.16M	$5.74M	$4.82M	$4.24M	$2.67M	$3.41M	$1.34M	$2.79M	-	$23.99K	$25.25K	$97.97K
Avg Forecast	$14.50M	$12.50M	$10.90M	$8.50M	$7.39M	$4.56M	$4.43M	$12.00M	$9.41M	$10.43M	$10.09M	$9.10M	$7.87M	$9.91M	$7.87M	$9.24M	$9.08M	$7.53M	$6.02M	$5.05M	$4.57M	$3.44M	$3.75M	$788.00K	$1.16M	$724.00K	$615.00K	$20.00K	$27.69K	$92.86K
High Forecast	$14.50M	$12.50M	$10.90M	$8.50M	$7.39M	$4.56M	$4.43M	$12.00M	$9.41M	$10.43M	$10.09M	$9.10M	$7.87M	$9.91M	$7.87M	$9.24M	$9.08M	$7.53M	$6.02M	$5.05M	$4.57M	$3.44M	$3.75M	$788.00K	$1.16M	$724.00K	$615.00K	$24.00K	$33.23K	$111.43K
Low Forecast	$14.50M	$12.50M	$10.90M	$8.50M	$7.39M	$4.56M	$4.43M	$12.00M	$9.41M	$10.43M	$10.09M	$9.10M	$7.87M	$9.91M	$7.87M	$9.24M	$9.08M	$7.53M	$6.02M	$5.05M	$4.57M	$3.44M	$3.75M	$788.00K	$1.16M	$724.00K	$615.00K	$16.00K	$22.15K	$74.28K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	17	9	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.94%	1.03%	1.09%	0.98%	1.01%	1.08%	1.19%	1.14%	1.06%	1.23%	0.71%	4.32%	1.16%	3.85%	-	1.20%	0.91%	1.06%

CASI Pharmaceuticals's average Quarter revenue forecast for Mar 23 based on 1 analysts is $9.10M, with a low forecast of $9.10M, and a high forecast of $9.10M. CASI's average Quarter revenue forecast represents a -40.36% decrease compared to the company's last Quarter revenue of $15.26M (Dec 22).

CASI Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Mar 19	Jun 15	Mar 05	Mar 04
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	17	9	10
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$12.54M	$-6.92M	$-7.61M	$-5.63M	$-4.38M	$-9.80M	$-6.48M	$-13.37M	$-13.72M	$-16.51M	$-8.18M	$-7.92M	$-12.77M	$-9.72M	$-7.65M	$-2.05M	$-5.33M	$-4.72M
Avg Forecast	$-12.16M	$-10.49M	$-9.14M	$-7.13M	$-6.20M	$-3.83M	$-3.72M	$-9.43M	$-7.90M	$-8.75M	$-8.46M	$-10.08M	$-3.13M	$-7.93M	$-6.30M	$-10.79M	$-7.26M	$-6.02M	$-4.82M	$-12.33M	$-3.65M	$-2.75M	$-3.00M	$-9.36M	$-928.97K	$-579.31K	$-7.80M	$-2.05M	$-4.88M	$-4.36M
High Forecast	$-12.16M	$-10.49M	$-9.14M	$-7.13M	$-6.20M	$-3.83M	$-3.72M	$-7.54M	$-7.90M	$-8.75M	$-8.46M	$-8.07M	$-2.50M	$-7.93M	$-6.30M	$-8.63M	$-7.26M	$-6.02M	$-4.82M	$-9.87M	$-3.65M	$-2.75M	$-3.00M	$-7.49M	$-928.97K	$-579.31K	$-6.24M	$-1.64M	$-3.91M	$-3.48M
Low Forecast	$-12.16M	$-10.49M	$-9.14M	$-7.13M	$-6.20M	$-3.83M	$-3.72M	$-11.31M	$-7.90M	$-8.75M	$-8.46M	$-12.10M	$-3.75M	$-7.93M	$-6.30M	$-12.94M	$-7.26M	$-6.02M	$-4.82M	$-14.80M	$-3.65M	$-2.75M	$-3.00M	$-11.23M	$-928.97K	$-579.31K	$-9.36M	$-2.47M	$-5.86M	$-5.23M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-4.01%	0.87%	1.21%	0.52%	0.60%	1.63%	1.35%	1.08%	3.76%	5.99%	2.73%	0.85%	13.74%	16.77%	0.98%	1.00%	1.09%	1.08%

1 analysts predict CASI's average Quarter EBITDA for Mar 23 to be $-10.08M, with a high of $-8.07M and a low of $-12.10M. This is -180.43% lower than CASI Pharmaceuticals's previous annual EBITDA (Dec 22) of $12.54M.

CASI Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Mar 19	Jun 15	Mar 05	Mar 04
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	17	9	10
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-18.50M	$-3.87M	$-7.68M	$-9.71M	$-6.21M	$-10.22M	$-6.95M	$-13.88M	$-14.20M	$-16.95M	$-8.69M	$-8.44M	$-12.90M	$-9.65M	$-8.17M	$-2.10M	$-5.46M	$-4.97M
Avg Forecast	$-6.35M	$-6.89M	$-7.30M	$-8.25M	$-8.11M	$-8.38M	$-8.52M	$-10.02M	$-3.24M	$-7.57M	$-6.76M	$-10.72M	$-3.06M	$-6.17M	$-8.52M	$-11.46M	$-7.66M	$-7.44M	$-9.80M	$-12.81M	$-9.46M	$-7.44M	$-10.82M	$-9.98M	$-14.87M	$-14.87M	$-8.17M	$-2.10M	$-5.00M	$-4.59M
High Forecast	$-6.35M	$-6.89M	$-7.30M	$-8.25M	$-8.11M	$-8.38M	$-8.52M	$-8.02M	$-3.24M	$-7.57M	$-6.76M	$-8.57M	$-2.45M	$-6.17M	$-8.52M	$-9.17M	$-7.66M	$-7.44M	$-9.80M	$-10.25M	$-9.46M	$-7.44M	$-10.82M	$-7.98M	$-14.87M	$-14.87M	$-6.54M	$-1.68M	$-4.00M	$-3.67M
Low Forecast	$-6.35M	$-6.89M	$-7.30M	$-8.25M	$-8.11M	$-8.38M	$-8.52M	$-12.02M	$-3.24M	$-7.57M	$-6.76M	$-12.86M	$-3.67M	$-6.17M	$-8.52M	$-13.75M	$-7.66M	$-7.44M	$-9.80M	$-15.37M	$-9.46M	$-7.44M	$-10.82M	$-11.97M	$-14.87M	$-14.87M	$-9.81M	$-2.51M	$-6.00M	$-5.50M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	6.05%	0.63%	0.90%	0.85%	0.81%	1.38%	0.71%	1.08%	1.50%	2.28%	0.80%	0.85%	0.87%	0.65%	1.00%	1.00%	1.09%	1.08%

CASI Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CASI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

CASI Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Mar 19	Jun 15	Mar 05	Mar 04
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	17	9	10
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$11.84M	$8.41M	$8.92M	$8.60M	$12.78M	$8.69M	$8.78M	$8.22M	$9.11M	$7.41M	$5.64M	$5.32M	$8.79M	$8.95M	$5.71M	$857.62K	$1.26M	$2.09M
Avg Forecast	$36.45M	$31.42M	$27.40M	$21.37M	$18.59M	$11.46M	$11.14M	$10.03M	$23.66M	$26.22M	$25.37M	$22.88M	$1.01M	$24.91M	$19.79M	$23.24M	$22.82M	$18.92M	$15.14M	$12.70M	$11.48M	$8.66M	$9.43M	$1.98M	$2.92M	$1.82M	$1.55M	$50.28K	$69.61K	$233.43K
High Forecast	$36.45M	$31.42M	$27.40M	$21.37M	$18.59M	$11.46M	$11.14M	$12.03M	$23.66M	$26.22M	$25.37M	$22.88M	$1.22M	$24.91M	$19.79M	$23.24M	$22.82M	$18.92M	$15.14M	$12.70M	$11.48M	$8.66M	$9.43M	$1.98M	$2.92M	$1.82M	$1.55M	$60.33K	$83.53K	$280.12K
Low Forecast	$36.45M	$31.42M	$27.40M	$21.37M	$18.59M	$11.46M	$11.14M	$8.02M	$23.66M	$26.22M	$25.37M	$22.88M	$811.78K	$24.91M	$19.79M	$23.24M	$22.82M	$18.92M	$15.14M	$12.70M	$11.48M	$8.66M	$9.43M	$1.98M	$2.92M	$1.82M	$1.55M	$40.22K	$55.69K	$186.74K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	11.67%	0.34%	0.45%	0.37%	0.56%	0.46%	0.58%	0.65%	0.79%	0.86%	0.60%	2.68%	3.01%	4.92%	3.69%	17.06%	18.11%	8.97%

CASI Pharmaceuticals's average Quarter SG&A projection for Mar 23 is $22.88M, based on 1 Wall Street analysts, with a range of $22.88M to $22.88M. The forecast indicates a 93.21% rise compared to CASI last annual SG&A of $11.84M (Dec 22).

CASI Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Mar 19	Jun 15	Mar 05	Mar 04
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	17	9	10
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-1.36	$-0.28	$-0.56	$-0.70	$-0.04	$-0.07	$-0.05	$-0.11	$-0.12	$-0.14	$-0.09	$-0.09	$-0.13	$-0.10	$-0.09	$-0.06	$-1.43	$-1.54
Avg Forecast	$-0.47	$-0.51	$-0.54	$-0.61	$-0.60	$-0.62	$-0.63	$-0.05	$-0.24	$-0.56	$-0.50	$-0.64	$-0.63	$-0.46	$-0.63	$-0.87	$-0.57	$-0.55	$-0.72	$-0.60	$-0.70	$-0.55	$-0.80	$-1.10	$-1.10	$-1.10	$-0.90	$-0.06	$-1.21	$-1.32
High Forecast	$-0.47	$-0.51	$-0.54	$-0.61	$-0.60	$-0.62	$-0.63	$-0.05	$-0.24	$-0.56	$-0.50	$-0.64	$-0.63	$-0.46	$-0.63	$-0.87	$-0.57	$-0.55	$-0.72	$-0.60	$-0.70	$-0.55	$-0.80	$-1.10	$-1.10	$-1.10	$-0.90	$-0.05	$-0.97	$-1.06
Low Forecast	$-0.47	$-0.51	$-0.54	$-0.61	$-0.60	$-0.62	$-0.63	$-0.05	$-0.24	$-0.56	$-0.50	$-0.64	$-0.63	$-0.46	$-0.63	$-0.87	$-0.57	$-0.55	$-0.72	$-0.60	$-0.70	$-0.55	$-0.80	$-1.10	$-1.10	$-1.10	$-0.90	$-0.07	$-1.45	$-1.58
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	2.16%	0.61%	0.89%	0.81%	0.08%	0.13%	0.07%	0.18%	0.17%	0.25%	0.11%	0.08%	0.12%	0.09%	0.10%	1.00%	1.18%	1.17%

According to undefined Wall Street analysts, CASI Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CASI previous annual EPS of $NaN (undefined).

CASI Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VBLT	Notable Labs	$0.16	$5.00	3025.00%	Buy
CLRB	Cellectar Biosciences	$1.61	$12.00	645.34%	Buy
CDTX	Cidara Therapeutics	$15.63	$24.00	53.55%	Buy
CASI	CASI Pharmaceuticals	$5.34	$6.00	12.36%	Buy

CASI Forecast FAQ

Is CASI Pharmaceuticals a good buy?

Yes, according to 2 Wall Street analysts, CASI Pharmaceuticals (CASI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CASI's total ratings.

What is CASI's price target?

CASI Pharmaceuticals (CASI) average price target is $6 with a range of $6 to $6, implying a 12.36% from its last price of $5.34. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CASI Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CASI stock, the company can go up by 12.36% (from the last price of $5.34 to the average price target of $6), up by 12.36% based on the highest stock price target, and up by 12.36% based on the lowest stock price target.

Can CASI Pharmaceuticals stock reach $8?

CASI's average twelve months analyst stock price target of $6 does not support the claim that CASI Pharmaceuticals can reach $8 in the near future.

What are CASI Pharmaceuticals's analysts' financial forecasts?

CASI Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $28.38M (high $28.38M, low $28.38M), average EBITDA is $-23.173M (high $-21.287M, low $-25.059M), average net income is $-35.031M (high $-33.027M, low $-37.034M), average SG&A $51.22M (high $53.22M, low $49.21M), and average EPS is $-1.9 (high $-1.9, low $-1.9). CASI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $46.4M (high $46.4M, low $46.4M), average EBITDA is $-38.921M (high $-38.921M, low $-38.921M), average net income is $-28.796M (high $-28.796M, low $-28.796M), average SG&A $116.65M (high $116.65M, low $116.65M), and average EPS is $-2.13 (high $-2.13, low $-2.13).

Did the CASI's actual financial results beat the analysts' financial forecasts?

Based on CASI Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $43.11M, beating the average analysts forecast of $34.9M by 23.53%. Apple's EBITDA was $-7.633M, missing the average prediction of $-28.141M by -72.88%. The company's net income was $-39.411M, beating the average estimation of $-29.211M by 34.92%. Apple's SG&A was $37.78M, missing the average forecast of $68.95M by -45.22%. Lastly, the company's EPS was $-2.89, beating the average prediction of $-2.583 by 11.87%. In terms of the last quarterly report (Dec 2022), CASI Pharmaceuticals's revenue was $15.26M, beating the average analysts' forecast of $7.87M by 93.85%. The company's EBITDA was $12.54M, missing the average prediction of $-3.127M by -500.93%. CASI Pharmaceuticals's net income was $-18.495M, beating the average estimation of $-3.058M by 504.71%. The company's SG&A was $11.84M, beating the average forecast of $1.01M by 1066.82%. Lastly, the company's EPS was $-1.36, beating the average prediction of $-0.63 by 115.87%